Network Analysis of DSM Symptoms of Substance Use Disorders and Frequently Co-Occurring Mental Disorders in Patients with Substance Use Disorder Who Seek Treatment.

ADHD borderline personality comorbidity conduct disorder gender differences network analysis personality disorders substance use disorders

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
19 May 2022
Historique:
received: 11 04 2022
revised: 10 05 2022
accepted: 15 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

Substance use disorders (SUD) often co-occur with other psychiatric conditions. Research on SUD and comorbid disorders generally flows from a categorical diagnostic or dimensional latent variable perspective, where symptoms are viewed as independent indicators of an underlying disorder. In contrast, the current study took a network analysis perspective to examine the relationships between DSM symptoms of SUD, ADHD, conduct disorder (CD), depression (MDD), and borderline personality disorder (BPD). In addition, we explored possible gender differences in the network structures of these symptoms. In a sample of 722 adult treatment-seeking patients with SUD from the International ADHD in Substance Use Disorders Prevalence Study (IASP) we estimated the network structure for 41 symptoms of SUD, ADHD, CD, MDD, and BPD. We described the structure of symptom networks and their characteristics for the total sample, and we compared the symptom networks for males and females. Network analyses identified seven clusters of symptoms, largely corresponding with the DSM diagnostic categories. There were some connections between clusters, mainly between some hyperactivity symptoms and CD and depressive symptoms. ADHD hyperactivity was most central in the symptom network. Invariance tests revealed no significant gender differences in the structure of symptom networks. The current findings support the categorical DSM classification of mental disorders in treatment-seeking patients with SUD. Future network analyses should include a broader range of symptoms and prospectively explore changes in the symptoms network of patients during treatment.

Sections du résumé

BACKGROUND BACKGROUND
Substance use disorders (SUD) often co-occur with other psychiatric conditions. Research on SUD and comorbid disorders generally flows from a categorical diagnostic or dimensional latent variable perspective, where symptoms are viewed as independent indicators of an underlying disorder. In contrast, the current study took a network analysis perspective to examine the relationships between DSM symptoms of SUD, ADHD, conduct disorder (CD), depression (MDD), and borderline personality disorder (BPD). In addition, we explored possible gender differences in the network structures of these symptoms.
METHOD METHODS
In a sample of 722 adult treatment-seeking patients with SUD from the International ADHD in Substance Use Disorders Prevalence Study (IASP) we estimated the network structure for 41 symptoms of SUD, ADHD, CD, MDD, and BPD. We described the structure of symptom networks and their characteristics for the total sample, and we compared the symptom networks for males and females.
RESULTS RESULTS
Network analyses identified seven clusters of symptoms, largely corresponding with the DSM diagnostic categories. There were some connections between clusters, mainly between some hyperactivity symptoms and CD and depressive symptoms. ADHD hyperactivity was most central in the symptom network. Invariance tests revealed no significant gender differences in the structure of symptom networks.
CONCLUSIONS CONCLUSIONS
The current findings support the categorical DSM classification of mental disorders in treatment-seeking patients with SUD. Future network analyses should include a broader range of symptoms and prospectively explore changes in the symptoms network of patients during treatment.

Identifiants

pubmed: 35629008
pii: jcm11102883
doi: 10.3390/jcm11102883
pmc: PMC9145186
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur Addict Res. 2020;26(4-5):191-200
pubmed: 32564016
JAMA Psychiatry. 2015 Dec;72(12):1219-26
pubmed: 26561400
Subst Use Misuse. 2011;46(6):808-18
pubmed: 21174496
World Psychiatry. 2017 Feb;16(1):5-13
pubmed: 28127906
Addict Biol. 2016 Sep;21(5):1052-9
pubmed: 26935336
J Psychiatr Res. 2012 May;46(5):659-66
pubmed: 22444600
Drug Alcohol Depend. 2014 Dec 1;145:127-33
pubmed: 25454410
Drug Alcohol Depend. 2011 Nov 1;118(2-3):92-9
pubmed: 21514751
Soc Work Public Health. 2013;28(3-4):424-39
pubmed: 23731429
Behav Brain Sci. 2010 Jun;33(2-3):137-50; discussion 150-93
pubmed: 20584369
Psychopharmacology (Berl). 2005 Oct;182(2):245-52
pubmed: 16001116
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
pubmed: 9204677
Psychol Methods. 2022 Apr 11;:
pubmed: 35404628
Neuropsychopharmacology. 2014 May;39(6):1527-37
pubmed: 24395021
PLoS One. 2015 Sep 14;10(9):e0137621
pubmed: 26368008
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Int J Methods Psychiatr Res. 2013 Sep;22(3):232-44
pubmed: 24022983
Compr Psychiatry. 1997 May-Jun;38(3):155-9
pubmed: 9154371
Biochem Pharmacol. 2007 Oct 15;74(8):1212-23
pubmed: 17689498
Annu Rev Clin Psychol. 2014;10:607-39
pubmed: 24437435
Annu Rev Clin Psychol. 2013;9:91-121
pubmed: 23537483
Arch Gen Psychiatry. 2007 May;64(5):566-76
pubmed: 17485608
J Am Acad Child Adolesc Psychiatry. 2000 Jan;39(1):49-58
pubmed: 10638067
Front Psychiatry. 2015 Feb 16;6:17
pubmed: 25762940
Child Adolesc Psychiatry Ment Health. 2016 Apr 11;10:8
pubmed: 27069507
J Affect Disord. 2016 Dec;206:331-349
pubmed: 27476137
Behav Res Methods. 2018 Feb;50(1):195-212
pubmed: 28342071
Drug Alcohol Depend. 2012 Apr 1;122(1-2):11-9
pubmed: 22209385
Soc Work Public Health. 2013;28(3-4):388-406
pubmed: 23731427
J Clin Psychiatry. 2006 Feb;67(2):247-57
pubmed: 16566620
Addict Behav. 2008 Sep;33(9):1104-12
pubmed: 18573617
Curr Psychiatry Rep. 2014 Mar;16(3):436
pubmed: 24526271
J Atten Disord. 2006 Feb;9(3):504-14
pubmed: 16481667
J Am Acad Child Adolesc Psychiatry. 2010 Dec;49(12):1189-201; quiz 1285
pubmed: 21093769
Drug Alcohol Depend. 2015 May 1;150:179-82
pubmed: 25746235
Psychol Med. 2010 Oct;40(10):1679-90
pubmed: 20059797
Sci Rep. 2014 Aug 01;4:5918
pubmed: 25082149
Curr Behav Neurosci Rep. 2020 Sep;7(3):109-127
pubmed: 33614396
Exp Neurol. 2014 Sep;259:64-74
pubmed: 24508560
Drug Alcohol Depend. 2013 Sep 1;132(1-2):29-37
pubmed: 23357742
Curr Addict Rep. 2021;8(1):89-99
pubmed: 33614395
Drug Alcohol Depend. 2015 Sep 1;154:1-13
pubmed: 26072219
Int J Drug Policy. 2019 Sep;71:103-112
pubmed: 31255918
Multivariate Behav Res. 2021 Mar-Apr;56(2):353-367
pubmed: 31179765
J Subst Abuse Treat. 2011 Dec;41(4):363-73
pubmed: 21742460
Curr Opin Psychiatry. 2012 May;25(3):181-6
pubmed: 22449761
Drug Alcohol Depend. 2016 Apr 1;161:230-7
pubmed: 26898186
Int J Eat Disord. 2019 Jun;52(6):701-711
pubmed: 30900758
Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109080
pubmed: 34634562
Addiction. 2014 Feb;109(2):262-72
pubmed: 24118292
Drug Alcohol Depend. 2014 Jan 1;134:158-166
pubmed: 24156882
Alcohol Clin Exp Res. 2014 Jan;38(1):275-84
pubmed: 23930695
Subst Use Misuse. 2012 Jun-Jul;47(8-9):1005-14
pubmed: 22676568
Clin Neuropharmacol. 2012 Sep-Oct;35(5):235-43
pubmed: 22986797
J Am Acad Child Adolesc Psychiatry. 2016 Mar;55(3):227-34.e4
pubmed: 26903256

Auteurs

Edith López-Toro (E)

PhD Program in Clinical Psychology, Universidad Carlos Albizu, P.O. Box 9023711, San Juan, PR 00902-3711, USA.

Casper J H Wolf (CJH)

Department of Psychiatry, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Department of Cognitive Neuroscience, Donders Institute for Brain Cognition and Behaviour, Radboud University, 6525 EN Nijmegen, The Netherlands.
Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), 6525 HR Nijmegen, The Netherlands.

Rafael A González (RA)

National Adoption and Fostering Service & National Conduct Problems Team, Michael Rutter Centre, South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK.
Centre for Psychiatry, Imperial College London, London W12 0NN, UK.

Wim van den Brink (W)

Department of Psychiatry, Amsterdam University Medical Center, Location Academic Medical Center, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands.

Arnt Schellekens (A)

Department of Psychiatry, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), 6525 HR Nijmegen, The Netherlands.

María C Vélez-Pastrana (MC)

PhD Program in Clinical Psychology, Universidad Carlos Albizu, P.O. Box 9023711, San Juan, PR 00902-3711, USA.

Classifications MeSH